Blue Vinyl pivots to Europe to track the threads of corporate power behind chemical science: the film spotlights Dr. Caesar Maltone, a biologist whose experiments the filmmakers say underpinned many lawsuits against vinyl plants, and singles out the Italian firm EniChem as a focal point. The documentary alleges that several large vinyl producers signed secrecy agreements designed to keep Maltone’s findings out of the public domain — a classic corporate playbook of suppressing inconvenient science. The film also details industry-set rules intended to limit legal exposure, most notably the adoption of a 1 ppm exposure ceiling, and includes Maltone’s blunt assessment that such numerical limits cannot eliminate the risk of exposure when production is running at scale. While the existence and scope of alleged secrecy pacts remain contested in documentation and industry rebuttals, the episode encapsulates the long-running fight between independent science, corporate legal strategy and communities demanding accountability.
Preparing the daily feature…
AI concept artworkArchive Record · 2000s
Dr. Caesar Maltone, EniChem, and Allegations of a Vinyl Industry Secrecy Pact
EniChem / Dr. Caesar Maltone (as featured in Blue Vinyl) / 2000s
Blue Vinyl pivots to Europe to track the threads of corporate power behind chemical science: the film spotlights Dr. Caesar Maltone, a biologist whose experiments the filmmakers say underpinned many lawsuits against vinyl plants, and singles out the Italian firm EniChem as a focal point. The documentary alleges that several large vinyl producers signed secrecy agreements designed to keep Maltone’s findings out of the public domain — a classic corporate playbook of suppressing inconvenient science. The film also details industry-set rules intended to limit legal exposure, most notably the adoption of a 1 ppm exposure ceiling, and includes Maltone’s blunt assessment that such numerical limits cannot eliminate the risk of exposure when production is running at scale. While the existence and scope of alleged secrecy pacts remain contested in documentation and industry rebuttals, the episode encapsulates the long-running fight between independent science, corporate legal strategy and communities demanding accountability.
The daily feature is taking an intermission. There’s still an entire archive to explore.
